Globally, chronic hepatitis B virus (CHB) infection causes chronic liver disease, fibrosis, cirrhosis, and hepatocellular carcinoma. Furthermore, many CHB patients have comorbid medical problems and varying degrees of renal impairment. The aim of the study was to evaluate the role of CHI3L1 in diagnosing liver fibrosis in the studied cases and assess the clinical and physiological factors during disease cases. 90 blood samples were collected from patients in the Dialysis Unit at Tikrit Teaching Hospital, Yathrib township, Aldhuluiya city, Al-Shuhada Health Center in the period from September 1, 2022, to February 28, 2023. 60 of these samples were obtained from patients with chronic hepatitis B virus diagnosed by doctors and divided into two groups: group one: 30 chronic hepatitis B patients (19 males, 11 females) aged 20-67; group two: 30 chronic hepatitis B patients with chronic kidney disease (CKD) (18 males, 12 females) aged 24-68. The control group consisted of 30 healthy individuals (19 males, 11 females) aged 20-55. Results indicated a substantial increase in CHI3L1 levels (174.41 ± 38.45a) in CHB patients compared to CKD patients (137.30 ± 37.8b) and controls (126.10 ± 30.0b) at P ≤ 0.05. A substantial rise in creatinine levels was observed in patients with chronic hepatitis B due to CKD (group 2) compared to CHB (group 1) and controls with a p-value ≤0.05. The mean ± SD of B.urea was 151.40 ± 24.2a in CKD patients (group 2), 31.26 ± 7.55b in CHB patients (group 1), and 27.54 ± 6.24b in controls (p-value ≤ 0.05). At p-value <0.05, CRP mean ± SD were 23.860 ± 4.220a in CKD patients (group 2), 4.040 ± 0.422b in CHB patients (group 1), and 4.200 ± 0.436b in controls. In chronic hepatitis B patients, CHI3L1 levels increase significantly. Chronic renal illness increases B.urea, creatinine, and CRP in chronic hepatitis B.
| Attachment | Size |
|---|---|
 01_ASSESSMENT OF SOME BIOMARKER OF LIVER FIBROSIS.pdf | 521.15 KB |
